BW373U86: A non-peptidic, systemically-active δ opioid agonist

CNS Drug Reviews

Volumn 2, Issue 1, 1996, Pages 52-74

  Negus, S Stevens ^a   Picker, Mitchell J ^b  

^a MCLEAN HOSPITAL   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

opioid receptors; BW373U86

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; BETA FUNALTREXAMINE; BREMAZOCINE; BW 373486; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN 2; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ENKEPHALIN[2 DEXTRO PENICILLAMINE 5 PENICILLAMINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; GUANINE NUCLEOTIDE; GUANOSINE TRIPHOSPHATE; GUANYLYLIMIDODIPHOSPHATE; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; MORPHINE; MU OPIATE RECEPTOR; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTREXONE; NALTRINDOLE; OPIATE ANTAGONIST; OPIATE PEPTIDE; QUADAZOCINE; SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; ANTINOCICEPTION; CONVULSION; DISCRIMINATIVE STIMULUS; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG SELECTIVITY; INFLAMMATION; INSTRUMENTAL CONDITIONING; LEARNING; LOCOMOTION; NONHUMAN; RECEPTOR AFFINITY; REINFORCEMENT; RESPIRATION DEPRESSION; REVIEW;

EID: 0004787283     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00290.x     Document Type: Review

References (106)

1. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991;258:299-303.
2. Abdelhamid EE, Takemori, AE. Characteristics of μ and δ opioid binding sites in striatal slices of morphine-tolerant and dependent mice. Eur J Pharmacol 1990;198:157-163.
3. 3H][2-D-penicillamine, 5-D-penicillamine]enkephalin binding to δ-opioid receptors in the rat brain and neuroblastomaglioma hybrid cell line (NG-108-15). Proc Natl Acad Sci, USA 1985;82:2543-2547.
4. Bot G, Chahl LA, Brent PJ, Johnston PA. Effects of intracerebroventricularly administered mu-, delta-and kappa-opioid agonists on locomotor activity of the guinea pig and the pharmacology of the locomotor response to U50,488H. Neuropharmacol 1992;9:825-833.
5. Brady JV, Griffiths RR, Hienz RD, Ator NA, Lukas SE, Lamb RJ. Assessing drugs for abuse liability and dependence potential in laboratory primates. In: Bozarth MA, ed. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer Verlag, 1987:45-86.
6. Broadbear JH, Negus SS, Butelman ER, DeCosta BR, Woods JH. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa opioid agonists in the mouse writhing assay. Psychopharmacol 1994;115:311-319.
7. 2 analysis of the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 1993;264:154-151.
8. Butelman ER, Negus SS, Gatch MB, Chang K-J, Woods JH. BW373U86, a δ-opioid agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys. Eur J Pharmacol 1995;277:285-287.
9. Cain DP, Boon F, Corcoran ME. Involvement of multiple opiate receptors in opioid kindling. Brain Res 1990;517:236-244.
10. Calcagnetti DJ, Holtzman SG. Delta opioid antagonist, naltrindole, selectively blocks analgesia induced by DPDPE but not DAGO or morphine. Pharmacol Biochem Behav 1991;38:185-190.
11. Calderon SN, Rothman RB, Porreca F, et al. Probes for narcotic receptor mediated phenomena: 19. Synthesis of (+)-4-[(aR)-a-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N- diethylbenzamide (SNC80): A highly selective, nonpeptide δ opioid receptor agonist. J Med Chem 1994;37: 2125-2128.
12. Chang K-J, Rigdon GC, Howard JL, McNutt RW. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 1993;267:852-857.
13. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the k opioid receptor. Science 1982;215:413-415.
14. 5]enkephalin and partial antagonism by naltrindole. J Pharmacol Exp Ther 1992;262:1004-1010.
15. Childers SR, Fleming LM, Selley DE, McNutt RW, Chang K-J. BW373U86: A nonpeptidic δ-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells. Mol Pharmacol 1993;44:827-834.
16. Childers SR. Opioid-coupled second messenger systems. In: Pasternak GW, ed. The Opiate Receptors. Clifton, NJ: Humana Press, 1988:231-271.
17. Colpaert FC. Drug discrimination: Methods of manipulation, measurement and analysis. In: Bozarth MA, ed. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer Verlag, 1987:341-372.
18. Comer SD, Hoenicke EM, Sable AI, et al. Convulsive effects of systemic administration of the delta opioid agonists BW373U86 in mice. J Pharmacol Exp Ther 1993a;267:888-895.
19. Comer SD, McNutt RW, Chang K-J, DeCosta BR, Mosberg HI, Woods JH. Discriminative stimulus effects of BW373U86: A nonpeptide ligand with selectivity for delta opioid receptors. J Pharmacol Exp Ther 1993b;267:866-874.
20. 3H]Naltrindole: A potent and selective ligand for labeling delta-opioid receptors. Brain Res 1993;604:160-164.
21. Cook TJ, Kitchen I, Hill RG. Effects of the delta-opioid receptor antagonist naltrindole on antinociceptive responses to selective delta-agonists in post-weanling rats. Br J Pharmacol 1992;107:573-576.
22. Cookson RF, Niemegeers CJE, Bussche GV. The development of alfentanil. Br J Anaesth 1983;55 Suppl 2:147s-155s.
23. Cotton R, Giles MG, Miller L, Shaw JS, Timms D. ICI 174,864: A highly selective antagonist for the opioid δ-receptor. Eur J Pharmacol 1984;97:331-332.
24. Cowan A, Zhu XZ, Mosberg HI, Omnaas JR, Porreca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther 1988;246:950-955.
25. Dauge V, Rossignol P, Roques BP. Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective μ and δ opioid peptides or kelatorphan an inhibitor of enkephalin-degrading-enzymes. Psychopharmacology 1988;96:343-352.
26. Davis M, Cedarbaum JM, Aghajanian GK, Gendelman DS. Effects of clonidine on habituation and sensitization of acoustic startle in normal, decerebrate and locus coeruleus lesioned rats. Psychopharmacologia 1977;51:243-253.
27. Davis M. Neurochemical modulation of sensory-motor reactivity: Acoustic and tactile reflexes. Neurosci Behav Rev 1979;4:241-263.
28. De Sarro GB, Marra R, Spagnolo C, Nistico G. Delta opioid receptors mediate seizures produced by intrahippocampal injection of ala-deltorphin in rats. Funct Neurol 1992;7:235-238.
29. Devine DP, Wise RA. Self-administration of morphine, DAMGO and DPDPE into the ventral tegmental area of rats. J Neurosci 1994;14:1978-1984.
30. Drower EJ, Stapelfeld A, Rafferty MF, DeCosta BR, Rice KC, Hammond DL. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic [D-penicillamine2-D-penicillamine5]enkephalin in the rat. J Pharmacol Exp Ther 1991;259:725-731.
31. Dykstra LA, Negus SS. Behavioral and pharmacological determinants of buprenorphine's effects on schedule-controlled behavior. In: Cowan A, Lewis JW, eds. Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York: Wiley-Liss, 1995:49-69.
32. Dykstra LA, Schoenbaum GM, Yarbrough J, McNutt R, Chang K-J. A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration. J Pharmacol Exp Ther 1993;267:875-882.
33. Emmerson PJ, Liu M-R, Woods JH, Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 1994;271:1630-1637.
34. Erspamer V, Melchiorri P, Falconieiri-Erspamer G, et al. Deltorphins: A family of naturally occurring peptides with a high affinity and selectivity for δ opioid binding sites. Proc Natl Acad Sci USA 1989;86: 5188-5192.
35. Fechter LD. The effects of L-dopa, clonidine and apormorphine on the acoustic startle reaction in rats. Psychopharmacologia 1974;39:331-344.
36. Frederickson RCA, Smithwick EL, Shuman R, Bemis G. Metkephamid, a systemically active analog of methionine enkephalin with potent opioid δ-receptor activity. Science 1981;211:603-605.
37. Haffmans J, Dzoljic MR. Effects of delta opioid antagonists on enkephalin-induced seizures. Pharmacology 1987;34:611-65.
38. 61-64 possessing selective agonist activity at μ opioid receptors. Eur J Pharmacol 1981;70:531-540.
39. Heyman JS, Mulvaney SA, Mosberg HI, Porreca F. Opioid δ-receptor involvement in supraspinal and spinal antinociception in mice. Brain Res 1987;420:100-108.
40. Heyman JS, Vaught JL, Mosberg HI, Haaseth R, Porreca F. Modulation of μ-mediated antinociception by δ agonists in the mouse: Selective potentiation of morphine and normorphine by (D-Pen,D-Pen)enkephalin. Eur J Pharmacol 1989;165:1-10.
41. Heyman JS, Vaught JL, Raffa RB, Porreca F. Can supraspinal δ-opioid receptors mediate antinociception? Trends Pharmacol Sci 1988;9:134-138.
42. 5)-enkephalin binding sites in rat brain membranes. Life Sci 1982;31:2359-2362.
43. Howell LL, Bergman J, Morse WH: Effects of levorphanol and several kappa-selective opioids on respiration and behavior in rhesus monkeys. J Pharmacol Exp Ther 1988;245:364-372.
44. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon, 1990:485-521.
45. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon, 1990:522-573.
46. Jenck F, Gratton A, Wise RA. Opioid receptor subtypes associated with ventral tegmental facilitation of lateral hypothalamic brain stimulation reward. Brain Res 1987;423:34-38.
47. Jiang Q, Mosberg HI, Porreca F. Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Pharmacol Exp Ther 1990;254:683-689.
48. 6)enkephalin and naltrindole 5′-isothiocyanate: Evidence for delta receptor subtypes. J Pharmacol Exp Ther 1991;257:1069-1075.
49. Katz JL, Goldberg SR. Effects of ethylketocyclazocine and morphine on schedule-controlled behavior in pigeons and squirrel monkeys. J Pharmacol Exp Ther 1986;239:433-441.
50. Kenakin TP. Pharmacologic analysis of drug-receptor interactions. New York: Raven Press, 1987.
51. Kiritsy-Roy JA, Marson L, Van Loon GR. Sympathoadrenal cardiovascular and blood gas responses to highly selective mu and delta opioid peptides. J Pharmacol Exp Ther 1989;251:1096-1103.
52. 5]enkephalin: A selective high affinity radioligand for δ-opioid receptors with exceptional specific activity. J Pharmacol Exp Ther 1991;258: 1077-1083.
53. Koster R, Anderson M, DeBeer EJ. Acetic acid for analgesic screening. Fed Proc 1959;18:412.
54. 3H]U-69,593: A highly selective ligand for the opioid k receptor. Eur J Pharmacol 1985;109:281-284.
55. Lee PHK, McNutt RW, Chang K-J. A nonpeptidic delta opioid receptor agonist, BW373U86, attenuates the development and expression of morphine abstinence precipitated by naloxone in rat. J Pharmacol Exp Ther 1993;267:883-887.
56. Locke KW, Holtzman SG. Behavioral effects of opioid peptides selective for mu or delta receptors. II. Locomotor activity in nondependent and morphine-dependent rats. J Pharmacol Exp Ther 1986;238: 997-1003.
57. 1-dependent stereotypies and stimulation of dopamine release in the nucleus accumbens. J Neurosci 1991;11:1565-1576.
58. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: Multiple agonists and receptors. Nature 1977;267:495-499.
59. Malmberg AB, Yaksh TL. Isobolographic and dose-response analyses of the interaction between intrathecal mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB). J Pharmacol Exp Ther 1992;263:264-275.
60. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta and kappa opioid receptors in rat forebrain and midbrain. J Neurosci 1987;7:2445-2464.
61. Mansour A, Lewis ME, Khachaturian H, Akil H, Watson SJ. Pharmacological and anatomical evidence of selective mu, delta and kappa opioid receptor binding in rat brain. Brain Res 1986;399:69-79.
62. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert P. The effects of morphine- and nalorphine-like drugs in the non-dependent and morphine-dependent dog. J Pharmacol Exp Ther 1976;197:517-532.
63. McGaugh JL, Introini-Collison IB, Castellano C. Involvement of opioid peptides in learning and memory. In: Herz A, ed. Opioids II. Berlin: Springer-Verlag, 1993:429-447.
64. McMillan DE, Morse WH. Some effects of morphine and morphine antagonists on schedule-controlled behavior. J Pharmacol Exp Ther 1967;157:175-184.
65. Meyer ME, Meyer ME. Behavioral effects of opioid peptide agonists DAMGO, DPDPE, and DAKLI on locomotor activities. Pharmacol Biochem Behav 1993;45:315-420.
66. Mickley GA, Mulvihill MA, Postler MA. Brain μ and δ opioid receptors mediate different locomotor hyperactivity responses of the C57BL/6J mouse. Psychopharmacology 1990;101:332-337.
67. Miyamoto Y, Portoghese PS, Takemori AE. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther 1993;264:1141-1145.
68. Mosberg HI, Hurst R, Hruby VJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward δ receptors. Proc Nat Acad Sci USA 1983;80:5871-5874.
69. Negri L, Noviello V, Angelucci F. Behavioural effects of deltorphins in rats. Euro J Pharm 1991;209: 163-168.
70. Negus SS, Burke TF, Medzihradsky F, Woods JH. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J Pharmacol Exp Ther 1993;267:896-903.
71. Negus SS, Butelman ER, Chang K-J, DeCosta BR, Winger G, Woods JH. Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 1994;270:1025-1034.
72. 2 and-bradykinin in rhesus monkeys. J Pharmacol Exp Ther 1995;274:805-814.
73. Negus SS, Mello NK, Portoghese PS, Lukas SE, Mendelson JH. Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 1995;273:1245-1256.
74. Olson GA, Olson RD, Kastin AJ, et al. Effects of an enkephalin analog on complex learing in the rhesus monkey. Pharmacol Biochem Behav 1979;11:341-345.
75. Overton DA. Applications and limitations of the drug discrimination method for the study of drug abuse. In: Bozarth MA, ed. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer Verlag, 1987:291-340.
76. Pakarinen ED, Woods JH, Moerschbaecher JM. Repeated acquisition of behavioral chains in squirrel monkeys: Comparisons of mu, kappa and delta opioid agonists. J Pharmacol Exp Ther 1995;272:552-559.
77. Picker MJ. Assessment of the kappa agonist and antagonist effects of mixed action opioids, mu opioids and a delta opioid in pigeons. Exper Clin Psychopharmacol 1996 (in press).
78. Picker MJ, Morgan D, Negus SS. Interaction between the discriminative stimulus effects of mu opioids and the delta opioid, BW373U86. NIDA Res Mono 1996 (in press).
79. Picker MJ, Dykstra LA. Discriminative stimulus effects of mu and kappa opioids in the pigeon: Analysis of the effects of full and partial mu and kappa agonists. J Pharmacol Exp Ther 1987;243:938-945.
80. Porreca F, Heyman JS, Mosberg HI, Omnaas JR, Vaught JL. Role of mu and delta receptors in the supraspinal analgesic effects of [D-Pen, D-Pen]enkephalin in the mouse. J Pharmacol Exp Ther 1987b;241:393-400.
81. Porreca F, Mosberg HI, Omnaas JR, Burks TF, Cowan A. Supraspinal and spinal potency of selective opioid agonists in the mouse writhing test. J Pharmacol Exp Ther 1987a;240:890-894.
82. Portoghese PS, Sultana M and Takemori AE. Naltrindole: A highly selective and potent non-peptide δ opioid-receptor antagonist. Eur J Pharmacol 1988;146:185-186.
83. Rogers H, Hayes AG, Birch PJ, Traynor JR, Lawrence AJ. The selectivity of the opioid antagonist, naltrindole, for δ-opioid receptors. J Pharm Pharmacol 1990;42:358-359.
84. cx binding site. Peptides 1991;12:359-364.
85. Shearman GT, Herz A. D-Ala, D-Leu-enkephalin generalizes to a discriminative stimulus produced by fentanyl but not ethylketocyclazocine. Pharmacol Biochem Behav 1982;16:249-252.
86. Schulteis G, Martinez JL Jr. ICI 174,864, a selective delta opioid antagonist, reverses the learning impairment produced by [leu]enkephalin. Psychopharmacology 1990;100:102-109.
87. Shippenberg TS, Bals-Kubic R, Herz A. Motivational properties of opioid: Evidence that an activation of δ-receptors mediates reinforcement properties. Brain Res 1987;436:234-239.
88. Snead OC. Opiate-induced seizures: A study of μ and δ specific mechanisms. Exp Neuro 1986;93:348-358.
89. Sofuoglu M, Portoghese PS, Takemori AE. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: Evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther 1991;257:676-680.
90. Spealman RD, Bergman J. Opioid modulation of the discriminative stimulus effects of cocaine: Comparison of m, k and d agonists in squirrel monkeys discriminating low doses of cocaine. Behav Pharmacol 1994;5:21-31.
91. Taber RI. Predictive value of analgesic assays in mice and rats. In: Braude MC, Harris LS, May EL, Smith JP, Villarreal JE, eds. Narcotic Antagonists: Advances in Biochemical Psychopharmacology. New York: Raven Press, 1974:191-209.
92. Taiwo YO, Levine JD. Kappa- and delta-opioids block sympathetically-dependent hyperalgesia. J Neurosci 1991;11:928-932.
93. Takasuna M, Negus SS, DeCosta BR, Woods JH. Opioid pharmacology of the antinociceptive effects of loperamide in mice. Behav Pharmacol 1994;5:189-195.
94. Tortella FC, Echevarria E, Robles L, Mosberg HI, Holaday JW. Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats. Peptides 1988;9:1177-1181.
95. Tortella FC, Robles L, Mosberg HI, Holaday JW. Electroencephalographic assessment of the role of δ receptors in opioid peptide-induced seizures. Neuropeptides 1984;5:213-216.
96. 5-enkaphalin (DADL) and dynorphin A(1-13). Psychopharmacology 1988;94: 32-37.
97. 5]enkephalin in the rat. Eur J Pharmacol 1993;231:143-144.
98. 5-enkephalin). Neuropharmacology 1989;10:1033-1039.
99. Wild KD, Fang L, McNutt RW, et al. Binding of BW 373U86, a non-peptidic δ opioid receptor agonist, is not regulated by guanine nucleotides and sodium. Eur J Pharmacol 1993;246:289-292.
100. Wild KD, McCormick J, Bilsky EJ, et al. Antinociceptive actions of BW373U86 in mouse. J Pharmacol Exp Ther 1993;267:858-865.
101. Wood PL, Charleson SE, Lane D, Hudgin RL. Multiple opioid receptors: Differential binding of μ, κ and δ agonists. Neuropharmacol 1981;20:1215-1220.
102. Xu H, Partilla JS, de Costa BR, Rice KC, Rothman RB. Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: Further evidence for delta receptor heterogeneity. Peptides 1993;14:893-907.
103. ncx binding sites in rat brain: Further evidence of homogeneity. Peptides 1992;13:1207-1213.
104. 3H]naltrindole binding to δ-opioid receptors in rat brain. Life Sci 1992;50:PL119-PL124.
105. Yanagita T. Self-administration studies on psychological dependence. Trends Pharmacol Sci 1980;1: 161-164.
106. Yeardon M, Kitchen I. Comparative binding of mu and delta selective ligands in whole brain and pons/ medulla homogenates from the rat: Affinity profiles of fentanyl derivatives. Neuropharmacol 1988;27: 345-348.